Top Markets
Coin of the day
Albireo Pharma, Inc. Albireo Pharma, Inc.

Albireo Pharma, Inc.

ALBO
주식 순위 #12828
Albireo Pharma, Inc. is a biopharmaceutical company with marketed products,... Albireo Pharma, Inc. is a biopharmaceutical company with marketed products, dedicated to researching, developing, and commercializing new treatments that modify bile acids. The company primarily targets rare liver diseases in children, as well as various other conditions affecting the liver or digestive system. Its portfolio includes Bylvay, a treatment approved for progressive familial intrahepatic cholestasis. Bylvay is also in advanced (Phase III) clinical trials for further pediatric indications such as biliary atresia and Alagille syndrome, which are both uncommon and serious childhood disorders. Additionally, Albireo offers Elobixibat, prescribed for the management of persistent constipation and other functional gastrointestinal issues. Albireo is further advancing its pipeline with A3907, currently undergoing early-stage (Phase I) clinical investigation for adult liver diseases, and A2342, a preclinical candidate designed to address adult viral and liver conditions. The company holds a licensing agreement with EA Pharma Co., Ltd. concerning the development and market rollout of Elobixibat. Albireo Pharma, Inc.'s headquarters are located in Boston, Massachusetts.
주가
$44.15
마지막 동기화: 2023-03-02
시가총액
$545.52M
변동 (1일)
-0.23%
변동 (1년)
0.00%
국가
US
거래 Albireo Pharma, Inc. (ALBO)

카테고리

Albireo Pharma, Inc. (ALBO)의 EPS
2026 기준 EPS TTM: 0
Albireo Pharma, Inc.의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 0입니다. 2026년 말에는 회사의 EPS가 0였으며, 이는 2026년의 EPS 0와 동일입니다.
Albireo Pharma, Inc.의 EPS 기록 (2026 ~ 2026)
매년 말의 EPS
연도 EPS 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 EPS
회사 EPS EPS 차이 국가
$17.32 -
US
$27.74 -
NL
$-5.29 -
AU
$-7.98 -
US
- -
CH